PROJECT44
12.2.2020 09:02:16 CET | Business Wire | Press release
project44, the global leader in advanced visibility for shippers and logistics service providers, has experienced significant growth across Europe following several recent announcements, including opening an office in Paris , adding several new team members , and building partnerships with global technology leaders .
Since acquiring Europe’s leading visibility provider, GateHouse Logistics, in 2018, project44 has increased global growth reaching more than 300 enterprise customers with over 20% in Europe, including leading brands such as Amazon, Coop, and Yazaki.
“With an increased need for real-time data and visibility across the entire supply chain, shippers and logistics service providers need a single global provider,” said Michael Gross, Director IT, Supply Chain and Logistics at Yazaki. “We’re excited for project44’s network to grow in Europe and beyond. Their plans for expansion are critical for supporting our global supply chain.”
With coverage in about 50 countries, integrations with over 760 telematics providers, and partnerships with global technology leaders such as SAP, project44 enables customers to tap into the most extensive visibility network across North America and Europe. With European carrier onboarding available in 16 languages and applications in 14 languages, p44’s comprehensive support ensures customers see the ROI of visibility in the fastest way possible.
To accelerate this European growth, project44 opened a Paris office in December of 2019 and has since retained several key hires for continued European expansion, reaching over 80 European-based employees in Aalborg, Amsterdam, Frankfurt, and Milan.
New team members include Regional VP of Sales Mickael Devena , Value Engineering Director Jatin Garg , Head of European Marketing Lorenzo Stranges, and Strategic Account Director Marco Tarpi . Devena and Garg bring extensive experience in transportation visibility from their time at Shippeo, while Stranges and Tarpi come from global SaaS leaders, including DocuSign and IBM respectively.
Michel Stekelenburg will also join the team as the Strategic Account Director for the Benelux region. In addition to several roles in supply chain technology, Stekelenburg serves as the President of the Benelux Roundtable for the Council of Supply Chain Management Professionals (CSCMP).
To lead this growing team, project44 has promoted Executive Vice President of Operations, Jørgen B Nielsen, to General Manager of Europe. With more than 20 years of experience with technical challenges and project execution in IT and telecom, Jørgen led GateHouse Logistics through rapid growth as Chief Operating Officer.
“Building on the GateHouse Logistics’s decade of significant success and expertise, project44 has continued to expand the European visibility market, delivering a seamless product and experience for our global customers,” said Jørgen. “As supply chains increase logistics and transportation operations across geographies, project44 will continue to expand globally and provide the coverage our customers need to effectively run their businesses.”
With over $110 million USD in capital, project44 will continue to explore additional international growth to deliver a seamless transportation visibility offering for global supply chains. By partnering with leading global carriers, project44 has already started gaining coverage beyond North America and Europe in Turkey, Russia, Ukraine, and Belarus. The visibility provider will also begin extending tracking connections in Morocco.
About project44
project44 is the world’s leading advanced visibility platform for shippers and logistics service providers. project44 connects, automates and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations are able to increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional Amazon-like experience to their customers. Connected to thousands of carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Truckload, Rail, Intermodal, and Ocean. To learn more, visit www.project44.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005086/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TVS Motor Company Returns to EICMA With New Models for Europe26.10.2026 12:45:00 CET | Press release
A year after its Milan debut, TVS Motor returns with a rapidly expanding European footprint and Italian sales up 110%Peyman Kargar to lead TVS Motor’s next phase of global growth as the company expands European footprint TVS Motor Company (TVSM), a global leader in two- and three-wheeler manufacturing, returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition. The company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET. The TVS stand is in Hall 18, Stand I64. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026990290/en/ TVS Motor Company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET at EICMA this year. EICMA 2025 marked the beginning of TVS Motor's European growth journey. Since then, the company has focused on establishing the foundations for long-term success, building its deal
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 12:00:00 CET | Press release
Improvements in symptoms of pain, stiffness, and range of motion were sustained through two yearsTumor responses remained robust1 and durable2Not intended for U.K.-, U.S.- or Canada-based media Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release
Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release
Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom